182 related articles for article (PubMed ID: 25542065)
1. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
[TBL] [Abstract][Full Text] [Related]
2. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
4. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
[TBL] [Abstract][Full Text] [Related]
5. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
[TBL] [Abstract][Full Text] [Related]
6. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
7. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
[TBL] [Abstract][Full Text] [Related]
8. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
[TBL] [Abstract][Full Text] [Related]
10. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
[TBL] [Abstract][Full Text] [Related]
11. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
12. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
Gillmore R; Stuart S; Kirkwood A; Hameeduddin A; Woodward N; Burroughs AK; Meyer T
J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
[TBL] [Abstract][Full Text] [Related]
13. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.
Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Marshall K; Lin M; Gebauer B; Chapiro J; Salem R; Geschwind JF
Transl Oncol; 2016 Oct; 9(5):377-383. PubMed ID: 27641641
[TBL] [Abstract][Full Text] [Related]
16. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
[TBL] [Abstract][Full Text] [Related]
18. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
[TBL] [Abstract][Full Text] [Related]
19. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
20. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
